Exhibit 99.1

                        Diagnostic Products Corporation
                   Announces Settlements with the SEC and DOJ



    LOS ANGELES--(BUSINESS WIRE)--May 20, 2005--Diagnostic Products
Corporation (NYSE:DP) (the "Company") today announced that it and its
wholly owned Chinese subsidiary, DPC (Tianjin) Co. Ltd. ("DePu"), had
reached agreements with, respectively, the United States Securities
and Exchange Commission ("SEC") and the United States Department of
Justice ("DOJ") to settle issues related to compliance with the U.S.
Foreign Corrupt Practices Act ("FCPA"). The Company has agreed to make
total payments of approximately $4.8 million in connection with these
settlements, the same figure previously announced and accrued by the
Company. This total includes a DOJ recommended fine of $2 million and
payments to the SEC consisting of disgorgement of $2.04 million plus
approximately $750,000 in prejudgment interest. In addition, DePu has
agreed with DOJ to enter a plea of guilty to a violation of the FCPA
subject to the approval of the federal court to which the matter will
be assigned. As part of the settlements, the Company and DePu have
agreed to maintain enhanced compliance programs which will be
confirmed by an independent monitor.
    The payments by DePu which gave rise to these actions were
promptly and voluntarily disclosed to the SEC and DOJ by the Company
as part of its voluntary and comprehensive remedial efforts after
current management in the United States discovered the payments. An
independent committee of the board directed the Company's
investigation of these matters, and the results were promptly
disclosed to the SEC staff and DOJ. The improper payments and guilty
plea are limited to DePu and its activities in the Peoples Republic of
China, but the Company's remedial efforts include expanded
Company-wide FCPA and ethics policies and procedures.
    These matters, along with their potential consequences, have
previously been publicly disclosed by the Company through its SEC
filings, beginning on February 14, 2003. A copy of the SEC settlement
and DPC's earlier disclosures are available on the Internet at
http://www.sec.gov.
    Michael Ziering, the Company's chairman, commented, "The Company
has taken remedial action with respect to its subsidiary's activities
in China, including implementing new and updated compliance programs.
Beginning with our voluntary disclosure of the facts underlying these
actions to the SEC and DOJ and throughout the governmental
investigations and settlement process, the Company has been fully
cooperative with the DOJ and SEC. We have also made it very clear that
improper activities will not be tolerated by the Company. We are
relieved that this chapter in the Company's history is drawing to a
close and that we can look forward to putting these matters to rest."
    Diagnostic Products Corporation, founded in 1971, is the global
leader dedicated primarily to immunodiagnostics. The Company designs
and manufactures automated laboratory instrumentation, which provides
fast, accurate results while reducing labor and reagent costs. The
Company's product menu includes a large variety of immunoassays
covering a broad range of clinical disease states including 360
specific allergens and allergy panels. Through partnerships with
manufacturers of chemistry systems and reagents, the Company also
addresses the chemistry and laboratory automation testing needs of its
customers. The Company sells its products to hospitals, clinics and
laboratories domestically and in more than 100 countries.
    Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially.
These factors include the effects of governmental and other actions;
the rate of customer demand for the Company's products; the Company's
ability to successfully market new and existing products; its
dependence on certain suppliers; domestic and foreign government
regulations; its ability to keep abreast of technological innovations
and to translate them into new products; competition; political and
economic instability in certain markets; including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC reports
and filings.



    CONTACT: Diagnostic Products Corporation
             James L. Brill, 310-645-8200